Small molecules that inhibit Vif-induced degradation of APOBEC3G

Virology Journal

Volumn 11, Issue 1, 2014, Pages

  Matsui, Masashi ^a   Shindo, Keisuke ^a   Izumi, Taisuke ^a,b   Io, Katsuhiro ^a   Shinohara, Masanobu ^a   Komano, Jun ^c   Kobayashi, Masayuki ^a   Kadowaki, Norimitsu ^a   Harris, Reuben S ^d,e   Takaori Kondo, Akifumi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b The Japan Foundation   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d Department of Biochemistry Molecular Biology and Biophysics ^*  (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

APOBEC3G; HIV 1; Small molecules; Vif

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; EPOXOMICIN; VIF PROTEIN; ANTIVIRUS AGENT; APOBEC3G PROTEIN, HUMAN; CYTIDINE DEAMINASE; ENZYME INHIBITOR; VIF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME DEGRADATION; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOBLOTTING; LUMINESCENCE; MOLECULE; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE; UBIQUITINATION; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; ISOLATION AND PURIFICATION; METABOLISM; PROTEIN DEGRADATION;

ANTIVIRAL AGENTS; CYTIDINE DEAMINASE; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; PROTEOLYSIS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84904216014     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-11-122     Document Type: Article

References (24)

1. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Gunthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT, Jama 2010 304 321 333
2. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Gunthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA, Jama 2012 308 387 402
3. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Tang MW, Shafer RW, Drugs 2012 72 1 e25
4. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. Gabuzda DH, Lawrence K, Langhoff E, Terwilliger E, Dorfman T, Haseltine WA, Sodroski J, J Virol 1992 66 6489 6495
5. Essential role of vif in establishing productive HIV-1 infection in peripheral blood T lymphocytes and monocyte/macrophages. Gabuzda DH, Li H, Lawrence K, Vasir BS, Crawford K, Langhoff E, J Acquir Immune Defic Syndr 1994 7 908 915
6. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Sheehy AM, Gaddis NC, Choi JD, Malim MH, Nature 2002 418 646 650
7. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L, Nature 2003 424 94 98 (Pubitemid 36834848)
8. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Stopak K, de Noronha C, Yonemoto W, Greene WC, Mol Cell 2003 12 591 601 (Pubitemid 37222482)
9. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF, Science 2003 302 1056 1060 (Pubitemid 37386201)
10. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Sheehy AM, Gaddis NC, Malim MH, Nat Med 2003 9 1404 1407 (Pubitemid 37466190)
11. Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex. Shirakawa K, Takaori-Kondo A, Kobayashi M, Tomonaga M, Izumi T, Fukunaga K, Sasada A, Abudu A, Miyauchi Y, Akari H, Iwai K, Uchiyama T, Virology 2006 344 263 266 (Pubitemid 43049613)
12. Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Jäger S, Kim DY, Hultquist JF, Shindo K, LaRue RS, Kwon E, Li M, Anderson BD, Yen L, Stanley D, Mahon C, Kane J, Franks-Skiba K, Cimermancic P, Burlingame A, Sali A, Craik CS, Harris RS, Gross JD, Krogan NJ, Nature 2011 481 371 375
13. T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Zhang W, Du J, Evans SL, Yu Y, Yu XF, Nature 2011 481 376 379
14. Retroviral restriction by APOBEC proteins. Harris RS, Liddament MT, Nat Rev Immunol 2004 4 868 877 (Pubitemid 39490762)
15. DNA deamination mediates innate immunity to retroviral infection. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH, Cell 2003 113 803 809 (Pubitemid 36724943)
16. APOBEC3G DNA deaminase acts processively 3' 5' on single-stranded DNA. Chelico L, Pham P, Calabrese P, Goodman MF, Nat Struct Mol Biol 2006 13 392 399 (Pubitemid 43881578)
17. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. Cullen BR, J Virol 2006 80 1067 1076 (Pubitemid 43134064)
18. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, Brown WL, Harris RS, J Virol 2011 85 11220 11234
19. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Albin JS, Harris RS, Expert Rev Mol Med 2010 12 4
20. Small-molecule inhibition of HIV-1 Vif. Nathans R, Cao H, Sharova N, Ali A, Sharkey M, Stranska R, Stevenson M, Rana TM, Nat Biotechnol 2008 26 1187 1192
21. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. Shindo K, Takaori-Kondo A, Kobayashi M, Abudu A, Fukunaga K, Uchiyama T, J Biol Chem 2003 278 44412 44416 (Pubitemid 37377191)
22. MDM2 is a novel E3 ligase for HIV-1 Vif. Izumi T, Takaori-Kondo A, Shirakawa K, Higashitsuji H, Itoh K, Io K, Matsui M, Iwai K, Kondoh H, Sato T, Tomonaga M, Ikeda S, Akari H, Koyanagi Y, Fujita J, Uchiyama T, Retrovirology 2009 6 1
23. APOBEC3G targets specific virus species. Kobayashi M, Takaori-Kondo A, Shindo K, Abudu A, Fukunaga K, Uchiyama T, J Virol 2004 78 8238 8244 (Pubitemid 38944307)
24. Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Haché G, Shindo K, Albin JS, Harris RS, Curr Biol 2008 18 819 824